InterMune Cut to Neutral at JPMorgan Chase & Co. (ITMN)
InterMune (NASDAQ:ITMN) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Tuesday, TheFlyOnTheWall.com reports.
ITMN has been the subject of a number of other recent research reports. Analysts at Jefferies Group upgraded shares of InterMune from an “underperform” rating to a “hold” rating in a research note on Monday. They now have a $74.00 price target on the stock, up previously from $25.00. Separately, analysts at William Blair raised their price target on shares of InterMune from $55.00 to $74.00 in a research note on Monday. Finally, analysts at Stifel Nicolaus downgraded shares of InterMune from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $53.00 price target on the stock, down previously from $53.80. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $56.30.
InterMune (NASDAQ:ITMN) opened at 72.85 on Tuesday. InterMune has a 52 week low of $10.95 and a 52 week high of $73.18. The stock has a 50-day moving average of $46.61 and a 200-day moving average of $36.93. The company’s market cap is $7.866 billion. InterMune also saw unusually large options trading activity on Monday. Stock traders purchased 5,253 call options on the company. This is an increase of approximately 156% compared to the average volume of 2,052 call options.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the previous year, the company posted ($0.77) earnings per share. The company’s revenue for the quarter was up 141.2% on a year-over-year basis. Analysts expect that InterMune will post $-2.75 EPS for the current fiscal year.
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of the stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total value of $375,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.